Bibliography
- Rosenthal L, McManus DD. Atrial fibrillation. Available from: http://emedicine.medscape.com/article/151066-print [Last accessed 30 December 2011]
- Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26
- European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
- Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935-41
- Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs 2004;13:415-26
- Køber L, Torp-Pedersen C, McMurray JJV, Increase mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87
- Hohnloser SH, Crijns HJ, van Eickels M, Effects of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
- Connolly SJ, Camm J, Halperin JL, Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76
- Sanofi provides Multaq Phase IIIb PALLAS Trial Update. Available from: http://en.sanofi.com/Images/28473_20110707_PALLAS_en.pdf [Last accessed 19 January 2012]
- Connolly SJ, Crijns HJ, Torp-Pedersen C, Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess, the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120:1174-80
- Nieuwlaat R, Hohnloser SH, Connolly SJ. Effect of dronedarone in patients with permanent atrial flutter during the ATHENA study [abstract]. Eur Heart J 2011;32(Suppl):618
- Davy JM, Herold M, Hoglund C, Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527.e1-9
- FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). Available from: http://www.fda.gov/drugs/drugsafety/ucm240011.htm [Last accessed 19 January 2012]
- Seviddio G, Bellanti F, Giudetti AM. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic Biol Med 2011;51:2234-42
- Levine TB, Giles T, Radzik E, Gali JK. Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. Cardiovasc Drug Ther 2010;24:449-58
- Nattel S. Dronedarone in atrial fibrillation – Jekyll and Hyde. N Engl J Med 2011;365:2321-2
- Flaker GC, Blackshear JL, McBride R, Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32
- FDA safety announcement re dronedarone labelling changes. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283933.htm [Last accessed 15 January 2012]
- EMA Sept 2011. Revised dronedarone guidelines/restrictions. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/09/WC500112800.pdf [Last accessed 15 January 2012]
- Page RL, Connolly SJ, Crijns HJ, Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol 2011;107:1019-22